The Eye-Opening Solution for Low-Lying Lids

Frustrated by eyelids that look tired or droopy? UPNEEQ is a new cosmetic product that’s changing the way people think about what’s possible when it comes to blepharoptosis, or low-lying lids.

The Eye-Opening Solution for Low-Lying Lids

Frustrated by eyelids that look tired or droopy? UPNEEQ is a new cosmetic product that’s changing the way people think about what’s possible when it comes to blepharoptosis, or low-lying lids.

The Eye-Opening Solution for Low-Lying Lids

Frustrated by eyelids that look tired or droopy? UPNEEQ is a new cosmetic product that’s changing the way people think about what’s possible when it comes to blepharoptosis, or low-lying lids.

What is Blepharoptosis?

Blepharoptosis is a common eyelid disorder that can affect adults of all ages and skin types. This disorder Can make eyes appear sleepy or tired, or make one eyelid appear more closed than the other. In some cases it can cause impaired vision and interferes with driving, reading, and other common activities that are necessary for everyday living. Until now, there has been little that can be done for this aggravating condition short of surgery.

For some, it is uncomfortable to bring up concerns about low-lying lids. They may not know the cause is a common medical condition and can be treated topically.

If you’re interested in learning more about UPNEEQ®, contact our office or call us and we can explain more about the product. You should always ask your dermatologist before trying a new cosmetic products in case there is a potential for a side effect.

We now carry UPNEEQ in our locations in Asheville and Hendersonville. Stop by to pick up your UPNEEQ during office hours!

Important Disclaimer

INDICATION

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
  • Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.

DRUG INTERACTIONS

  • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.